influenza A (H5N1) virus monovalent vaccine, subvirion

The monovalent subvirion H5N1 influenza vaccine is an inactivated, split-virion (subvirion) vaccine designed to provide active immunization against the H5N1 subtype of Influenza A virus. Developed by Sanofi Pasteur, it was the first H5N1 vaccine to receive FDA approval (in 2007) for the U.S. Strategic National Stockpile. The vaccine is produced in embryonated chicken eggs and contains hemagglutinin (HA) from the A/Vietnam/1203/2004 strain. While the initial approved formulation was unadjuvanted and required a high dose (90 µg) for immunogenicity, subsequent clinical development efforts have focused on lower-dose formulations combined with adjuvants (such as aluminum hydroxide) to improve the immune response and extend the vaccine supply during a potential pandemic.

Other names

monovalent subvirion H5N1 influenza vaccineH5N1 influenza vaccineH-5N1 influenza vaccineH 5N1 influenza vaccineA/Vietnam/1203/2004 vaccineSanofi Pasteur H5N1 vaccine